Showing 4111-4120 of 9323 results for "".
- Topical Collagen Powder May Be Effective for Wound Closurehttps://practicaldermatology.com/news/collagen-may-be-effective-for-wound-closure/2460091/Collagen powder is as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures, according to a first-of-its-kind study published in the Journal of Drugs in Dermatology. Researchers investigated the efficacy of topical collagen powder compared to primary closure on th…
- Hair Loss Breakthrough: 3D-Printing Creates “Hair Farms”https://practicaldermatology.com/news/hair-loss-breakthrough-research-uses-3d-printing-to-create-hair-farms/2460083/Columbia researchers have created a way to use 3-D printing to create “hair farms” in a dish, which could open up hair restoration surgery to more people, including women, and improve the way pharmaceutical companies search for new hair growth drugs. The findings, which appear in Nature Communicat…
- FDA Clears Allergan's CoolTone Devicehttps://practicaldermatology.com/news/fda-clears-allergans-cooltone-device/2460075/The FDA has cleared Allergan plc's CoolTone device for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone is also indicated for strengthening, toning and firming of buttocks and thighs. “By partnering with Allergan, I can offer my pa…
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue to talk about acne and share her Proactiv journey …
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary endpoint at week 24,…
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s end. The …
- Pivotal Phase 3 Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne Meet All Efficacy Endpointshttps://practicaldermatology.com/news/pivotal-phase-3-trials-of-trifarotene-in-patients-with-moderate-facial-and-truncal-acne-meet-all-efficacy-endpoints-2/2460056/Results from the pivotal Phase 3 PERFECT 1 and PERFECT 2 clinical trials of once-daily trifarotene 50 µg/g cream in patients with moderate acne on the face and trunk, published in the June issue of Journal of the American Academy of Dermatology, met all primary and secondary efficacy endpoints. Tri…
- ASA Honors Outstanding Researchershttps://practicaldermatology.com/news/asa-honors-outstanding-researchers/2460029/Luis Diaz, MD of the University of North Carolina, Chapel Hill and John Stanley, MD of the University of Pennsylvania took home the American Skin Association’s David Martin Carter Mentor Award at the Annual Meeting of the Society for Investigative Dermatology. ASA President Dr. David Norris presen…
- Higher BMI Linked to Psoriasishttps://practicaldermatology.com/news/higher-bmi-linked-to-psoriasis/2460014/Excess weight is a contributing factor for developing psoriasis, and the greater the body mass index (BMI), the higher the chance of getting the disease, according to a new study. To investigate the causal relationship between BMI and psoriasis, the researchers used Mendelian randomization. They f…
- FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-duobrii-for-treatment-of-plaque-psoriasis/2460009/The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical lotion that contains a unique combination of halobetasol propionate…